title: Value of serum human epidermal growth factor receptor 2 (HER2)/neu testing for early prediction of response to HER2/neu-directed therapies is still an open one and deserves further study in large prospective trials.
authors.forename: Suhail M
authors.initials: SM
authors.lastname: Ali
authors.forename: Kim
authors.initials: K
authors.lastname: Leitzel
authors.forename: Allan
authors.initials: A
authors.lastname: Lipton
authors.forename: Walter P
authors.initials: WP
authors.lastname: Carney
authors.forename: Wolfgang J
authors.initials: WJ
authors.lastname: Köstler
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D005260:Female; D006801:Humans; D011446:Prospective Studies; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab